InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
About InteKrin (http://www.InteKrin.com):
InteKrin Therapeutics is a privately-held clinical stage biopharmaceuticalcompany focused on the development and commercialization of novel drugs forthe treatment of diabetes, obesity and metabolic disease. The company's leadprogram is INT131, a late-stage non-TZD SPPARM (Selective PeroxisomeProliferator-Activated Receptor Modulator). INT131 is the result of anextensive molecular design effort to address the problematic safety concernsof TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R)(rosiglitazone), which while efficacious are associated with weight gain,edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 wasspecifically selected for its ability to separate powerful PPAR anti-diabeticefficacy from these serious TZD side effects.
INT131 is a next-generation insulin sensitizer that addresses insulinresistance, a key etiological feature in the onset and subsequent progressionof type 2 diabetes. Treating and improving insulin sensitivity in diabeticpatients by activating PPAR-gamma is an important therapeutic tool forphysicians, providing powerful glucose control and durability of effect. As aSPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned tosafely reduce insulin resistance, addressing an important unmet medical need.
InteKrin expects to complete enrollment of its 360 patient, 24-week,placebo-controlled Phase 2b study of INT131 at four doses compared to 45mgActos in Q1 09 and to have final results later this year.
To learn more about InteKrin, visit http://www.InteKrin.com.
SOURCE InteKrin Therapeutics, Inc.
You May Also Like